Introduction
Recent progress in the knowledge of the molecular basis The syndrome of multiple endocrine neoplasia of of cancer has led to recognition of the existence of two type 1 (MEN 1)
classes of genes whose mutations may be at the origin of malignant transformation. Overexpression of onco-In 1954, Wermer reported for the first time the simulgenes on the one hand, and inactivating mutations or taneous occurrence of adenomas of the anterior pituitdeletions of tumour suppressor genes on the other, may ary, the parathyroids, and the islets of the pancreas in cause transformation of specific target cells. At least 10 a man and four women of the same family. He tumour suppressor genes are known at present, includ-concluded that this adenomatosis was probably of ing Wilms' tumour (WT ) suppressor gene, von Hippel-genetic origin [6 ] . He underlined that 'in contrast to Lindau (VHL) gene, and retinoblastoma (RET) gene, what is seen in the usual case of 1°HPTH, the to name but a few of particular interest to the clinical parathyroids show involvement of all four glands.' He nephrologist. Loss of function of these genes, which hypothesized that the mode of inheritance was probusually imposes some constraint on the cell cycle making ably dominant, due to a single gene, with a high degree cells proliferate more rapidly, promotes the occurrence of penetrance and expressivity, and postulated that the and the progression of various types of cancer, such as gene should play a role in the control of normal and Wilms' tumour [1] , renal-cell carcinoma [2, 3] , and pathological growth of endocrine tissue. sporadic malignant parathyroid tumour [4] . MEN 1 is an autosomal dominant familial cancer Among the familial forms of hyperparathyroidism, syndrome characterized by tumours of parathyroids, multiple endocrine neoplasia (MEN ) constitues a fascin-pancreas, duodenal endocrine, and anteropituitary ating group of proliferative multicentric disorders target-cells. It is defined as the occurrence of at least two ing various endocrine glands, dispersed endocrine cells major lesions of classical MEN 1 in the same patient and, in some cases, neurons and their supporting ele-and one lesion in first degree relatives or one lesion ments [5] . MEN includes three syndromes, namely either in parathyroids, pancreas, or pituitary in three MEN 1 ( Wermer's syndrome) [6 ] , MEN 2A (Sipple's first-degree relatives [11] . In unselected autopsies, the syndrome) and MEN 2B. MEN 1 is characterized by incidence of MEN 1 seems to be up to 0.25% [12] . the association of endocrine adenomas in the para-HPTH is the most common clinically evident componthyroid, the pituitary, and the pancreas or small intestine ent of MEN 1 and its prevalence is over 90% at the (see below). In MEN 2A enlarged parathyroids are age of 40. Diagnosis of MEN 1-related HPTH can be associated with thyroid medullary carcinoma and delayed by several years because hypercalcaemia generphaeochromocytoma, and in MEN 2B [5] medullary ally remains asymptomatic in the early stage of the thyroid carcinoma is associated with phaeochromo-disease [13] . Unlike sporadic HPTH which affects cytoma and ocular/oral neuromas with gastrointestinal more frequently women, the HPTH of MEN 1 occurs ganglioneuromatosis. They are usually inherited as equally in both sexes, and patients with MEN 1 are autosomal dominant traits but may also occur in a usually younger at the time of diagnosis [5, 7, 9] . MEN sporadic fashion. Interestingly, tumours are preceded 1-associated enlargment of the parathyroid is multiin their development by phases of endocrine-cell glandular and asymmetric, frequently with one or two hyperplasia [5, [7] [8] [9] .
glands of normal or minimally enlarged size [14] . From a histopathological point of view, parathyroid lesions have evidence of gastrin-producing tumours within the glands removed from uraemic patients with severe secondary HPTH [23, 24] . pancreas and the duodenum, carcinoid tumours of the As to the underlying genetic molecular mechanisms, lung, thymus and gastrointestinal tract, adenomas or an activation of the PRAD1 (cyclin D1) oncogene has hyperplastic nodules of the adrenal [15] and thyroid been demonstrated to occur in 5-18% of primary paraglands, multiple soft tissue lipomas [5] , and multiple thyroid adenomas [25, 26 ] . The activation is driven by facial angiofibromas. The latter are also observed in the aberrant placement of this gene in close proximity tuberous sclerosis [16 ] . Except for gastrinomas, most to enhancer elements of the PTH gene. A number of of these tumours are non-metastasizing neoplasias.
various somatic gene mutations are probably involved However, with regard to parathyroid tumours it is of in other primary adenomas as well as in secondary note that although removal of a single enlarged gland HPTH [26] [27] [28] [29] . Loss of activation of the RB gene or may result in the temporary amelioration of the signs of another gene on 13q is an important factor in the and symptoms of HPTH, there is a high frequency of genesis of parathyroid carcinoma and aggressively growrecurrence in patients with MEN 1 who have been ing benign parathyroid tumours [30] [31] [32] . In patients thus treated [17, 18] .
with MEN 2A and MEN 2B, germline mutations at specific sites in the RET proto-oncogene have been
Cloning of menin gene
shown. In these syndromes, in contrast to what is observed in MEN 1, activating germline mutations Initially, comparison of leukocyte-derived and tumour-are responsible of tumoral proliferation [5] . It is derived RFLPs showed loss of heterozygosity at chro-interesting to note that mutations of the RET gene mosome locus 11q13, with either total or subtotal are also responsible for autosomal dominant form of allelic deletions, in parathyroid tumours and malignant Hirschsprung disease [33] . Moreover, renal agenesis or insulinomas from patients with MEN 1 [19] [20] [21] . The dysgenesis is observed in mice homologous for a targeted hunt for the MEN 1 gene took another 9 years. It was mutation in RET [34] . In hyperparathyroidism-jaw eventually cloned in 1997 by two independent groups tumour syndrome, a rare autosomal dominant condition [10, 11] . Located in the pericentric region on the long characterized by recurrent parathyroid tumours and arm of chromososme 11, band 11q13, in an interval mandibular or maxillary tumours, parathyroid carcinbounded telomerically by D11S4936 [10] or D11S1783 oma and cystic or tumoral lesions of the kidney are not [11] and centromerically by PYGM, the MEN 1 gene rare [35, 36 ] . contains 10 exons and encodes a ubiquitously expressed Mutations of the MEN 1 gene in germline DNA are 2.8-kilobase transcript [10, 11] . The predicted protein detected not only in MEN 1 families but also in encoded by MEN1 gene, named 'menin', contains 610 sporadic cases of MEN 1 [37] . A somatic mutation in amino acids, has apparently no similarities with previ-the MEN 1 gene and an allelic deletion over chromoously described proteins, and is expressed ubiquitously some 11q13 have been found in 20% of sporadic in adult tissues [10] . Over 40 different germ-line muta-parathyroid tumours in one recent study [38] and in tions distributed throughout all the open reading frame up to 40% in another [39] . This suggests that somatic have been found in investigated MEN 1 kindreds, point mutations of this gene may be a relatively suggesting the absence of founder effect [11] . The common event. sequence abnormalities are either insertional or deletional frameshift, non-sense, or miss-sense mutations MEN 1 gene, tumour monoclonality and cancer which would predict a premature truncation of the menin protein, consistent with its putative role as Several facts argue for a role of the MEN 1 gene in the a tumour suppressor gene. Combined pedigree and development of a variety of common tumour types. tumour studies demonstrated that the tumour-related Allelic loss over chromosome 11q has been found in allelic deletions of chromosome 11 occurred on the several malignancies, including breast, kidney, ovary chromosome inherited from the normal parent and not and cervix cancer, as well as in sporadic parathyroid, from the affected parent. Therefore it is very likely that pituitary and other endocrine tumours, in accordance familial MEN 1 tumours develop according to the twowith the ubiquitous presence of menin in a large number hit mutation theory of Knudson. Thus far no correlation of tissues [40] . Thus MEN-1-associated tumours may between genotype and phenotype was found.
be the tip of the iceberg; menin may be a key cell-cycle regulator in many tissues and its inactivation by somatic
Other gene defects and importance of MEN 1 gene mutations could be an important step in the developin hyperparathyroidism ment of many common tumour types [41] . However, several physiopathological problems conRecent results of molecular genetic studies in para-cerning the role of the MEN 1 gene in tumour genesis thyroid tumour biology have provided major insights remain: first, monoclonality of parathyroid nodules into primary and secondary HPTH. Using a method associated with MEN 1 does not appear to be necessary based on DNA analysis to demonstrate X-chromosome to allow autonomous growth [42] . Second, the stimulainactivation, it has been shown that primary para-tion of endothelial cell proliferation in endocrine tissue thyroid adenomas are exclusively monoclonal tumours by basic fibroblast growth factor (bFGF ) released into the peripheral circulation [43-45] has not been [22] . This is also the case in the majority of parathyroid 16 . Darling T, Skarulis M, Steinberg S, Marx S, Spiegel A, Turner M.
attributed to the MEN 1 gene up to now. The role of Multiple facial angiofibroma and collagenomas in patients with circulating bFGF-like autoantibodies in growth stimumultiple endocrine neoplasia type 1. Arch Dermatol 1997; 133: lation of endocrine cells of some cases of MEN 1 [853] [854] [855] [856] [857] associated with prolactinoma must be confirmed 17 
Conclusion and future
Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: [85] [86] [87] Tracking the tumour suppressor gene MEN-1 (menin) 20 consensus has been reached concerning indication and higher than 160/95 mmHg, is present in more than mode of blood pressure treatment in acute stroke. 70% of the patients with acute stroke [1] , and mostly disappears spontaneously in the days following stroke onset without specific therapy [2] . The mechanisms Arguments not to treat hypertension responsible for this blood-pressure elevation are unclear. Central mechanisms, catecholamine and Justification and rationale for not treating hypertension corticosteroid release, mental stress of acute illness, in acute stroke are based on the fear of worsening the and hospital admission are discussed [3] . A rise in neurological deficit [5,6 ] as a result of reduced cerebral systemic blood pressure in the acute phase of stroke blood flow (CBF ), because autoregulation mechanisms may be a physiological response to a decreased blood are defective. Physiologically the CBF is kept constant flow in the ischaemic penumbra surrounding the core by a mechanism called autoregulation at a level of of infarction. A higher initial systemic blood pressure 55-60 ml/100 g/min in a range of mean systemic arterhas been found in patients with cerebral haemorrhage ial pressure between 55 and 125 mmHg. In patients compared to those with cerebral infarct, and also in with chronic hypertension, autoregulation starts at a patients with known and treated hypertension [1, 2] .
higher systemic pressure. Below this threshold a direct The preventive role of antihypertensive treatment in relationship between cerebral blood flow and mean reducing morbidity and mortality from stroke is well arterial pressure exists [7] . In the acute phase of stroke, established. Treatment that causes a long-term reduc-a central core of brain infarction is surrounded by the tion in diastolic blood pressure of 5-6 mmHg results area of ischaemic penumbra, in which the autoregulain a 35-40% fall in the risk of stroke [4] . In the setting tion of the cerebral blood pressure is impaired (see of acute stroke, blood pressure reduction is one of the Figure 1 ). Perfusion in this area is too low to maintain most common therapies. Too frequently blood pressure normal neuronal function, but sufficient to keep the is reduced too rapidly, with little attention to the neurons alive for a short period of time. The blood patient's prior blood pressure status or to the end flow in the ischaemic penumbra is pressure dependent in the ischaemic penumbra, thereby causing ischaemic haemorrhagic transformation, especially in anticoagulated patients, are reasons to treat high systolic blood pressures [10, 11] . In experimental animals, inducing hypertension may cause worsening of the oedema associated with focal ischaemia, but these findings are inconsistent [9] . It has never been shown that reduction in arterial pressure will lessen oedema formation. Oedema is a result of ischaemia. In addition, reducing blood pressure worsens ischaemia, therefore ischaemia-induced oedema may also be favoured by low blood pressure.
Extreme and persistent hypertension occurs more often in case of intracerebral haemorrhage than infarc- Fig. 1 . Regional cerebral blood flow (ml/100 g/min) in the baboon tion. Some authors suggest treatment if systolic blood hemisphere immediately after middle cerebral artery occlusion. The pressure >200 mmHg and diastolic blood pressure central core of severe ischemia (A) is surrounded by a zone with less reduction in blood flow in which flow may be at or just above >120 mmHg associated with intracerebral bleeding, critical levels for neuronal function or viability (B). There is little (i) to limit the development of vasogenic oedema due or no flow reduction in the remainder of the hemisphere (C ) to disruption of the blood-brain barrier in the isch-
aemic area around the haemorrhage [4] , and (ii) to reduce the rate of rebleedings. Considering all arguments and the lack of controlled Intracerebral bleeding studies, at the moment only pathophysiologically based Hypertensive encephalopathy/malignant hypertension therapeutic guidelines can be formulated. Currently most authors suggest treating only extremely elevated blood pressure. In the American Heart Association's tissue to become infarcted, and result in even greater Guidelines for the management of patients with acute neuronal damage.
ischemic stroke [12] , in a patient with ischaemic stroke, In patients with high-grade stenoses of the internal antihypertensive treatment is recommended if mean carotid artery, low blood pressure may case haemoarterial blood pressure is >130 mmHg, or if systolic dynamically induced infarction. In addition partial blood pressure is >220 mmHg. Brott and MacCarthy occlusion of an arterial vessel may create decreased recommend starting antihypertensive treatment if sysand turbulent flow in the remaining patent portions of tolic blood pressure exceeds 240 mmHg or diastolic the vessel. Decreasing blood flow due to hypotension blood pressure 140 mmHg [13] . will facilitate thrombus formation and potentially There are, of course, exceptions to the rule not to extend the original occlusion [5] .
treat even moderate hypertension in ischaemic stroke (see Table 1 ). Aortic dissection and also an acute
Arguments to treat hypertension
myocardial infarct may require lowering of the systemic blood pressure as a life-saving therapy. Hypertensive stroke patients receiving thrombolytic therapy have a The risk of inducing brain oedema, associated with uncontrolled hypertension, and the risk of secondary higher rate of intracerebral haemorrhage [14, 15] . With Table 2 . Suggested algorithms for treatment of acute hypertension from the literature Brott et al. [13] Diastolic BP>140 mmHg Nitroprusside 0.5-10 mg/kg/min i. shown in Tables 2 and 3. 25(9): [1901] [1902] [1903] [1904] [1905] [1906] [1907] [1908] [1909] [1910] [1911] [1912] [1913] [1914] Patients with acute stroke respond sensitively to 13 without posing added risk [13] . Introduction study has suggested that they were sufficiently serious to lead to the interruption of the treatment in approxiThe polyvalent intravenous immunoglobulin preparamately 10% of the patients [7] . Life-threatening sidetions (IvIg) were introduced in the seventies for replaceeffects are very rare and have been reported in the ment therapy in patient with primary immunoglobulin form of anaphylaxis (hypotension, bronchospasm), deficiency. An ingenious observation made in 1980 particularly in patients with IgA deficiency. The transsuggested that the administration of high-doses IvIg mission of viral hepatitis has been a troublesome may have immunomodulatory functions [1] . Idiopathic problem over the years. Despite modern manufacturing thrombocytopenic purpura was the first disease in which practices, the recent transmissions of hepatitis C by a the positive effects could be demonstrated [2] Repeatedly, it has been suggested that the presence of The early years other substances co-purified with IgG and present in IvIg contribute to the modulatory properties of IvIg. The first report of an acute renal failure after IvIg Recently, transforming growth factor beta ( TGF-b) concerned a patient with cryoglobulinaemia type II was found in all batches of various IvIg preparations (monoclonal IgM rheumatoid factor/polyclonal IgG) [4] . Immunoglobulins have been shown to be a carrier who had high levels of the monoclonal rheumatoid for TGF-b, and TGF-b is a potent immunosuppressive factor [9] . This patient developed a lymphoma and agent in many animal studies. From these observations, hypogammaglobulinaemia ( low IgG). She received it does not require an extraordinary leap of imagination chemotherapy, but had several episodes of pneumonia. to suggest that part of the effects of IvIg is due to the Fifteen grams of gammaglobulin were infused over 4 h. presence of TGF-b.
Oliguria with rising serum urea and creatinine developed Despite the vast literature on the subject, the evi-within 24 h. A renal biopsy performed after 5 days dence-based indications of IvIg are limited and include revealed that the glomerular capillaries were occluded only a few autoimmune diseases, e.g. Guillain-Barré with hyaline thrombi surrounded by polymorphonuclear syndrome, idiopathic thrombocytopenic purpura, leukocytes. Some arterioles and other small blood vesdermatomyositis and Kawasaki syndrome. In many sels were also filled with similar hyaline thrombi. other diseases IvIg have been tried with some or only Ultrastructural and immunofluorescence studies showed limited success (see University Hospital Consortium clearly that the material was cryoglobulin including Expert Panel review [5] ).
the rheumatoid factor, with surrounding complement The side-effects of IvIg are diverse, most are due to activation. The worsening renal function was relieved a too fast infusion rate of the immunoglobulins [6 ] . only after plasmapheresis. This observation corresponds The incidence of side-effects of IvIg is reported to be to rare descriptions made in patients with cryoglobulinaaround 5-15%. The majority of these side-effects are emia in whom the very high levels of cryoglobulins are responsible for capillary obstruction in the glomeruli. 
increase in creatinine was seen in all patients; it was are very high in plasma so that immune complexes/ aggregates are formed [10] . To add the antigen (IgG) not, however, accompanied by a commensurate rise in urea [18] . Three of the patients were studied in more may fuel the reaction leading to immune precipitation, as seen in that unique patient. From this observation it details during the two courses of IvIg infusions they received. Before infusions, the creatinine clearance was is also evident that cryoglobulinaemia type II is a contra-indication for IvIg. However, it should be noted higher than the inulin clearance because of the known tubular secretion of creatinine, particularly in patients that this contra-indication is not limited to high-dose IvIg treatment, but is also true for correction of low with heavy proteinuria. After IvIg infusions on five occasions a marked decrease of creatinine clearance, IgG levels even with a small amount of IvIg.
The next reports of possible renal side-effects of IvIg but not of inulin clearance, was noted. Only once did creatinine and inulin clearance decrease simultaneously. concerned patients with autoimmune diseases. The worsening of a nephrotic syndrome in a patient with These observations suggested that the IvIg preparation used interfered with the secretion of creatinine, i.e. SLE and exacerbation of haematuria/proteinuria in a patient with Henoch-Schö nlein purpura were men-produced a tubular dysfunction. In nine patients treated for glomerulonephritis Rostoker et al. [19] monitored tioned by Jordan, but not documented [11] . Another patient with SLE had worsening of renal function after the urinary excretion of tubular enzymes during IvIg infusions. They found a significant rise in urinary alanine high doses of IvIg, which recovered after plasma exchange. No histology was performed [12] . Thus, aminotranspeptidase after the treatment, and noted a small increase in creatinine in three patients, again until 1990, apart from the few patients mentioned, there was no indication that IvIg may damage the without a concomitant increase in urea. Taken together these data favoured the hypothesis that IvIg induces kidney other than by immune mechanisms of injury.
Because of several preliminary positive reports con-proximal tubular dysfunction. A more severe form might lead to transient renal failure in a time frame cerning the treatment of various types of nephritis, we embarked at that time on a trial on IvIg in glomerulo-corresponding to the recovery of tubular function after an acute injury, i.e. some weeks. nephritis with nephrotic syndrome. The trial was stopped due to lack of efficiency after six patients had been enrolled. One of the patients presented a transient
The sucrose hypothesis
non-oliguric acute renal failure. This prompted us to review all the data which brought two further cases to our attention [13] . There was no evidence in any of The histological findings in renal biopsies provided further arguments against the notion that the mechanthese patients for an immune reaction such as rash or arthralgia. In all three patients, renal function returned ism of renal failure after IvIg was glomerular deposition of immune reactants. Except for the first patient to pre-IvIg levels within 2-3 weeks.
described above, none of the biopsies showed evidence for an immunological reaction. The lesions mostly
Anecdotal observations of acute renal failure
concerned the proximal tubules with marked swelling of the cells, cytoplasmic vacuolization and degeneration of proximal tubular epithelial cells. The lumina After this observation, there was a series of case reports, which all indicated that the administration of were occluded by the swollen cells. The histology corresponded to what is known to pathologists as high-dose IvIg can be followed by acute renal failure (see reviews [14, 15] ). Fifty patients have been included 'osmotic nephrosis'.
Sucrose was rapidly considered a candidate for such in the review by Cayco et al. [15] , and new cases continue to be published [16, 17] . This flurry of reports histological lesions, since most patients with transient renal failure after IvIg had received sucrose-containing leaves no doubts about a direct causal link. In fact, it is surprising that this side-effect had not been reported preparations. Sucrose is a disaccharide which is filtered by the glomerulus and reabsorbed by tubular cells. It during the first 10 years of the use of high-dose IvIg. The incidence of renal failure is certainly low, however, is remarkable that the brush borders of the tubular cells do not contain disaccharidase so that the sucrose as suggested by a retrospective analysis of all patients receiving IvIg for neurological disease [7] . Of 88 cannot be degraded within the cells. In 1942 it was described for the first time that sucrose caused renal patients receiving 1-18 courses of IvIg for a total of 650 infusions, there was one case of acute reversible lesions [20] . The 'sucrose nephrosis' was characterized by marked swelling and vacuolization of proximal renal failure in a 62-year-old diabetic patient who had had a high creatinine concentration (1.9 mg/dl ) and tubular cells [21, 22] . Several experimental studies analysed the ultrastructural features of sucrose toxicity, proteinuria (761 mg/24 h) before therapy.
but the mechanisms underlying sucrose toxicity were not clearly understood. Other hyperosmotic solutions,
Experimental data
such as mannitol and dextran, are known to cause renal failure which is characterized by similar renal lesions. However, the hyperosmolality of the IvIg per se There are only few experimental studies which address the question as to why IvIg produces renal failure. is unlikely to be the major culprit, since the patients do not present a true hyperoncotic syndrome. The use of new preparations of IvIg containing no sucrose may well stop the 'endemic' renal failure after IvIg. hypertonic IvIg solutions are quickly diluted in blood. Furthermore, if it was hypertonicity causing tubular Until then, beware of the sugar! damage, one would expect to see the most severe lesions in the distal proximal tubule, where the osmolality due to reabsorption of water and sodium is highest. References But histological examinations indicated that the prox- 
Introduction
(iv) What therapeutic interventions can be carried out to limit the deleterious effects of PMN accumulation? In There is still no specific therapy for acute renal failure order to ascertain the actual importance of PMN in (ARF ) despite the multiple investigative efforts to ARF, the real magnitude of PMN accumulation in renal clarify its complex pathophysiology. ARF occurring ischaemia/reperfusion processes must be determined. during kidney ischaemia/reperfusion is the classical Conventional histological techniques may not be suffipathological entity in which polymorphonuclear neu-cient to demonstrate increased amounts of PMN, and trophil (PMN ) recruitment during reperfusion appears more specific techniques, such as measurements of specific to be a significant mediator of kidney injury. enzymatic activities, e.g. myeloperoxidase [4, 5] , or histochemical stainings, e.g. naphthol AS-D chloroacetate esterase [2] , may be required to detect PMN infiltration.
Evidence for the role of PMN in acute renal failure In our experience, myeloperoxidase activity determination is significantly more sensitive than optical microEven though diverse communications have shown that scopy [4, 5] for studying PMN activation during renal PMN can be increased and activated in renal ischaemia/ ischaemia/reperfusion. The possibility exists that myeloreperfusion [1, 2] , definitive evidence which demonstrates peroxidase released by activated PMN becomes attached that PMN have a necessary role of their own in the to cell membranes and, therefore, may be increased even outcome of ARF is still lacking. As a more general in the absence of histological evidence of the presence interpretation, it is not yet clear whether the mechanisms of PMN. involved in the ischaemia/reperfusion response are actuActivation of PMN is a critical component of several ally different, in the early phase, from those triggered by processes causing organ damage. In fact, PMN accumuinfectious agents or trauma. Furthermore, the participa-lation is a common finding, not only in ARF but also in tion, relative importance and sequence of interactions of other acute renal diseases. In this regard, PMN activation the individual agents potentially involved in the activation and/or accumulation is an important feature in entities of PMN in the setting of ischaemia/reperfusion and ARF as different as post-streptococal glomerulonephritis [6 ], need to be clarified. The issue of the importance of PMN Puumala hantavirus-induced nephropathia epidemica [7] activation is not without therapeutic consequences. For or haemolytic uraemic syndrome [8] . In acute glomeruloexample, the use of biocompatible membranes has been nephritis, adhesion molecules, granule enzymes, reactive oxygen radicals, lipid metabolites and cytokines of encouraged for patients with ARF requiring haemodiaactivated neutrophils and monocytes mediate glomerlysis, due to their lower PMN-activating properties, which ular capillary constriction and occlusion, with different might result in improved recovery of renal function [3] .
degrees of tubular damage and subsequent ARF [6 ] . In The following are elementary questions pertinent to haemolytic-uraemic syndrome, verotoxin-1 modulates the issue of PMN accumulation in ARF. (i) What are leucocyte-endothelium interaction, thus increasing leucothe mechanisms responsible for triggering, maintaining cyte adhesion and up-regulating adhesive proteins on and relieving PMN accumulation? (ii) What are the endothelial surface membranes [8] . It is difficult, however, conditions which determine the injuring potential of these to ascertain whether PMN accumulation is or is not PMN? (iii) What is the actual pathophysiological impormandatory for the complete development of these pathologies and to identify the putative common points and ARF and other conditions. precursor, -arginine, suggesting the inhibition of [18] , who demonstrated that both ET-1 and The precise mechanisms leading to the activation neuropeptide Y are able to prime PMN oxidative of PMN in ischaemia/reperfusion are insufficiently metabolism and the fMLP-induced rise in [Ca2+] i . It characterized. During tissue reperfusion, a host of is of interest that ET-1 alone failed to stimulate reactive oxygen free radicals, autacoids and autocrine, para-oxygen species generation [16 ] , favouring the possibilcrine and endocrine mediators and cytokines are ity of a limited, selective degree of stimulation, instead released, which result in changes in the adhesive proper-of a massive PMN activation. ties of the endothelium, in the chemotactic attraction Additional studies have provided further information of cells from the blood and in localized and selective to clarify the mechanisms by which ET-1 acts on PMN. changes in vessel permeability. Leucocyte adhesion ET-1 induces dose-dependent PMN aggregation starting molecules appear to facilitate PMN recruitment in this 1 min after ET-1 exposure [19] . This aggregation is setting. Studies using monoclonal antibody, antisense accompanied by a significant increase in the production oligonucleotide and gene 'knock-out' techniques of platelet-activating factor (PAF ) by PMN. In this indicate that blockade of CD11/CD18 integrins and regard, PAF receptor antagonists significantly blunted intercellular adhesion molecule-1 (ICAM-1) attenuates the ET-1-induced [Ca2+] i peak and aggregation [19] . In ARF in some experimental models of renal ischaemia addition, ET-1 stimulates PMN adhesion to cultured [9,10]. Linas et al. have shown that neutrophil retention, endothelial cells (increase of 1×105±1±104 neutrophils activation and renal injury can be completely prevented per well ) [20] . The ET-induced adhesion was blocked with anti-ICAM-1 [11] . These authors also demon-(83±6%) by the anti-CD18 antibody TS1/18 and by strated that previous activation of PMN is an important several anti-a-subunit antibodies. The expression of condition to provoke renal PMN accumulation during CD18 and CD11b on the neutrophil surface was also ischaemia/reperfusion. This phenomenon might be of increased by ET-1, suggesting another putative funcparticular importance in the case of ARF in patients tional effect of the ET-1-mediated activation of the with sepsis, who might present both renal hypoperfusion neutrophils. The effect of ET-1 on PMN adherence was and PMN activation [11, 12] . In fact, PMN obtained confirmed in studies from other groups [21] . More from ischaemic kidneys were able to induce ARF when evidence was needed to determine whether the findings perfused in isolated kidneys, suggesting that the role of with cultured endothelial cells were also valid in condi-PMN in the whole phenomenology of ARF is remark-tions closer to those in vivo. Experiments with the ably important. The fact that fully developed ARF isolated rabbit heart model provided this evidence, by occurs in neutropenic subjects raises a caveat in attribut-showing that the increased neutrophil adhesion to the ing an important role to PMN. endothelium in the presence of ET-1 also occurred in a whole organ model. Neutrophil accumulation was also
Mechanisms of neutrophil activation in ischaemia/
ET-1's effect by NO. The role of ET-1 as a priming reperfusion factor for PMN was illustrated further by Hafstrom et al.
Agents potentially involved in the accumulation of
inhibited by an anti-TS1/18 antibody [4] . Wright et al. neutrophils in acute renal failure: endothelin 1 [22] found that the potency of PMN chemotactic activit-
(ET-1) and nitric oxide (NO)
ies of the endothelin peptides are ET-1=ET-2>ET-3. They also found that ET-1 fails to stimulate PMN respiratory burst, degranulation or arachidonic acid The release of endothelin-1 is increased in ischaemia/ metabolism [22] . reperfusion conditions. The simultaneous occurrence Further data pursuing the functional implications of of increased concentrations of ET-1 and PMN infiltra-ET-1 activation of PMN demonstrated an effect on tion after ischaemia/reperfusion suggests the possibility enzyme release. Immunostaining of human PMN that both are related phenomena. In fact, the adminisincubated with ET-1 showed an intense, spreading tration of ET-1 antiserum or ET-1 antagonist has been pattern of anti-human granulocyte elastase within the shown to ameliorate the functional deficits resulting cytosol [23] . This reflects PMN activation by ET-1, from ischaemic ARF [13, 14] . The observations of followed by the release of granule contents. ET-1 Morita et al. [15] , who have shown that untreated and caused a dose-and time-dependent increase in PMN activated PMNs led to a 1.4-and 6.3-fold increase in intracellular calcium and elastase release into the ET-1 mRNA levels in endothelial cells, respectively, medium. Moreover, ET-1-activated neutrophils were suggest that in conditions of direct PMN-endothelial shown to cause massive destruction in umbilical cords cell contact, an intensified expression of the ET-1 gene [23] . These results suggest the existence of a previously might occur.
undescribed pathway to produce endothelial injury and The first hint regarding a possible effect of ET-1 tissue damage in conditions with high blood levels of on PMN was provided by Ishida et al. [16 ] who endothelin. However, as occurred with other effects of communicated that ET-1 stimulates the production of ET-1 on PMN, the data on exocytotic enzyme release superoxide anion by the chemotactic peptide, Nwere not uniformly positive in experiments by different formylmethionyl-leucyl-phenylalanine (fMLP). Other authors [24] . authors found that ET-1 provoked a [Ca2+] i transient The interactions between the effects of ET-1 and on PMN [17] . The ET-1-induced [Ca2+] i transient was blunted when the PMN were pre-treated with the NO those of -arginine are critical in different tissues; data concerning these interactions were, however, not failure, inducible NO formation and PMN accumulaavailable in neutrophils. A separate study examined tion are related phenomena. In a recent study in such interactions in human PMN [25] . Some of the isolated perfused rat kidneys, Linas et al. [28] provided experimental findings relevant to this review showed more data on this issue. Their experiments disclosed that in human PMN: (i) ET-1 and the chemoattractant that after 20 min of ischaemia/60 min reperfusion, NO peptide fMLP induce both the metabolism of worsens ischaemic injury in the absence of PMN, but -arginine to -citrulline and cyclic GMP (cGMP) NO prevents the PMN component of ischaemic renal formation; (ii) the ET-1-induced cGMP production is injury by blocking PMN retention and the deleterious inhibited by the -arginine antagonist, NG-mono-effects of activated PMN on glomerular and tubular methyl--arginine, suggesting the involvement of NO; function [28] . and (iii) the ET-1-or fMLP-induced NO/cGMP stimu-
The heterogeneity of the available information on lation is critically dependent on the availability of the subject of vasoactive mediators, PMN and ARF -arginine [25] .
highlights the fact that outcome of ARF depends on ET-3 activates PMN migration at concentrations the individually variable extent of damage and effici-∏10 nM. The stimulating effect of ET-3 appears to be ency of the repair. In this setting, it is rather naïve to mainly chemotactic, in contrast with that of ET-1, consider PMN only as potentially injuring agents. In which is mainly chemokinetic [24] . Extracellular cal-fact, it must be remembered that recruitment or activacium and protein kinase C, protein tyrosine kinase, tion of macrophages and PMN in the area of injury and phosphatase activity are involved in the ET-results in scavenging of cellular debris, control of 1-induced activation of neutrophil migration. The ETA coagulation phenomena and local release of growth receptor antagonist, BQ123, the ET receptor agonist, factors to promote regenerative repair [29] . This positsarafotoxin S6c, and the ETB receptor antagonist, IRL ive view of some aspects of PMN action will have to 1038, inhibit ET-3-activated migration, suggesting that be considered in order to complete the picture of the the ETA and the ETB receptor are both involved in role of PMN in ARF. the effects of ET-3 on PMN [24] .
Recent studies have shown that the effect of antigen-related mechanism [4] . It is of further interest that an increased accumulation of PMN was detected in the hearts of rabbits with ischaemia/reperfusion References injury or following intrarenal ET-1 infusion. These effects were both blocked by a specific anti-ET-1 anti-
Definition and pathology
15% of patients, however, present with massive haemorrhage. In at least 90% of episodes bleeding stops Angiodysplasia, also referred to as vascular ectasia or spontaneously [4] . arteriovenous malformation, is a distinct pathological Microscopically angiodysplasia consists of dilated, and clinical entity. It is the most common vascular thin-walled, distorted vessels lined by endothelium and, abnormality of the gastrointestinal tract and probably infrequently, by a thin layer of smooth muscle. the most frequent cause of recurrent lower-intestinal Submucosal veins and venules are primarily affected. bleeding in otherwise healthy elderly patients.
It is presumed that some of these lesions become more Angiodysplasia is likely a degenerative lesion extensive over time; when capillaries dilate, precapillary associated with ageing and (other than hereditary spincters lose their competency, and a small arteriohaemorrhagic telangiectasia, Osler-Weber-Rendu) not venous fistula is produced. associated with angiomatous lesions of other viscera
The cause for angiodysplasia is unknown. It has or the skin.
been suggested that repeated intermittent low-grade In people with normal renal function lesions are obstruction of submucosal veins at the point where most often found in the caecum or ascending colon, they cross the muscular layers of the colon leads to usually multiple, and smaller than 10 mm in diameter.
development of the lesion [5] . Since increased wall In large series of colonoscopies angiodysplasias have tension is presumed to result in obstruction of subbeen detected in 0.2-2.9% of 'non-bleeding patients' mucosal veins, according to Laplace's principle the and in 2.6-6.2% of patients who underwent endoscopy caecum and right colon, having a large diameter, for anaemia, faecal occult blood loss or intestinal appear to be a preferred site for development of haemorrhage [1] [2] [3] . In general, bleeding from angio-angiodysplasia. It is unlikely, however, that this mechanism plays an important role in the development of It is likely that, at least in younger patients, some or even the majority of these vascular lesions, especially Sensitivity for endoscopy and angiography for diagnosis of angiodysplasia is not exactly known. Based those in the stomach, the duodenum, and the small intestine are congenital in origin [6, 7] . on small series, however, sensitivity of endoscopy is much higher compared to angiography (approximately 80% vs 20% [12] [13] [14] Diagnosis of angiodysplasia can be difficult. Because detecting approximately one-third of angiodysplastic lesions in the small intestine [15] , or a special longer the lesions do not distort the mucosa or submucosa, in principle they cannot be detected by barium contrast push enteroscope. In problem patients with ongoing bleeding undiagnosed by conventional methods both studies. Colonoscopy and angiography are the only effective means for diagnosis. Because of its favourable jejunum and ileum can be inspected by using a normal colonoscope intraoperatively. safety profile, diagnostic efficacy and therapeutic capability colonoscopy (or upper gastrointestinal endoBiopsy of angiodysplasic lesions should be avoided, since endoscopically derived biopsies containing only scopy) has emerged as the method of choice for evaluating patients suspected of having bleeding angio-mucosal tissue are usually non-diagnostic but may provoke haemorrhage. Radionuclide scans can be used dysplasia [8] . Endoscopically, lesions appear flat or slightly raised above the mucosal surface, cherry red in patients actively bleeding (especially from the small bowel ) to localize the bleeding site. However, scans in colour, and usually 2-10 mm in size. Multiple angiodysplasias are present in a high percentage of are unable to identify the cause of bleeding. patients (40-75% [7] ).
The lesions may be round in contour, stellate, or Angiodysplasia and renal failure having sharply circumscribed fern-like margins. Falsenegative endoscopic examinations may occur in severly Angiodysplasia is an important cause of haemorrhage anaemic or volume-depleted patients because the dis-in chronic renal failure observed in up to 19-32% of tinctive red colour of angiodysplasia may be absent patients in retrospective reports [16] [17] [18] [19] . Lesions are [9] . Therefore those patients should receive trans-usually multiple, often located in the stomach and fusions prior to the endoscopic examination. When duodenum, but can affect the colon and the jejunum performing the procedure, one must differentiate angio-as well, and have a high tendency of rebleeding dysplasia from suction marks and other artefacts (25-47% [17, 18] ). It is unknown whether the incidence which may be induced by minor trauma during the of angiodysplasia or its tendency to bleed is increased examination. Careful inspection on insertion of the in chronic renal failure and whether formation of instrument, rather than relying on assessments made angiodysplasic lesions precedes or follows onset of during the withdrawal phase of the procedure can renal failure. One study, including 59 patients with minimize this problem. Active bleeding from angiodys-chronic renal failure and upper gastrointestinal haemplasia and the presence of an adherent clot on a lesion orrhage identified angiodysplasia as the most frequent are definite signs. Presence of fresh blood in a segment cause of recurrent bleeding in patients with renal failure of the gastrointestinal tract in the absence of concomit-(53% [17] ). Interestingly in this study, 39% of patients ant pathological findings or recurrent episodes of on dialysis and 70% of renal transplant recipients had haemorrhage and no possible source detected other associated clotting disorders. Other comorbid condithan angiodysplasia, is also persuasive evidence. tions often found in renal patients as congestive heart The most common angiographic sign is an early and failure, diabetes mellitus, coronary artery disease, and prolonged opacification of a draining vein, recognized hypertension may increase the risk of bleeding [20] . in 85-90% of visualized lesions [10, 11] , which is indicative of an arteriovenous communication. Other angioTreatment graphic criteria include clusters of small arteries and a vascular tuft. However, definite proof that a visualized lesion is the cause for bleeding requires observation of Since the natural history of angiodysplasia in renal extravasation of contrast material in the gastrointesti-failure is unknown, lesions found incidentally in nal lumen. This is an uncommon finding, seen in only patients who have never bled before should be left 20% or less of patients [10], since angiographic visual-untreated. On the other hand taking into account the ization requires a bleeding activity of at least 1 ml/min. acquired platelet defect that may arise in chronic renal It should be noted that the angiographic criteria men-failure, patients should avoid taking aspirin or nontioned above are not specific for angiodysplasia but steroidal anti-inflammatory agents. can be found in patients with Crohn's disease, polyps,
In patients with active bleeding or those who have bled and do not show another identifiable cause and cancer as well. endoscopic haemostatic therapy is generally the initial patients with recurrent bleeding from angiodysplasia form of treatment. Different endoscopic devices have received 50 or 100 mg 17-beta-oestradiol transdermally been used and described in non-randomized reports. twice a week for a period of 2 months [29] . Bleeding Injection sclerotherapy is widely available, cheap, and activity in all patients either ceased or improved as relatively simple to perform. To avoid deep ulceration shown by a reduced number of transfusions needed. only small amounts of the sclerosing agent (e.g. sodium Again no adverse reactions were observed over 2 months tetradecyl sulphate, 0.5 ml ) should be used. The full of therapy. However, it has to be stressed that controlled spectrum of complications of this method have not trials on the use of hormonal therapy for bleeding been defined so far. Concerns have been raised regard-angiodysplasia in renal patients are lacking and the ing possible consequences of injection of sclerosant well-known side-effects of oestrogens including gynaecothrough the bowel wall into the peritoneal cavity [9, 21] . mastia, fluid retention, vaginal bleeding, thrombosis, Monopolar electrocoagulation using hot biopsy for-and stroke should not be overlooked. ceps may cause serious complications in up to 9% of Other attempts to stop major bleeding from angiodyspatients, including perforation of the bowel in approxi-plasias include transcatheter embolization and intramately 3% [2, 22, 23] . Therefore, other devices should arterial or intravenous infusion of vasopressin, which be preferred. Bipolar contact probes have several may cause serious side-effects such as ischaemia of advantages. Published experience with these devices in mesenteric, coronary, and peripheral vessels. Patients the treatment of angiodysplasia is, however, limited so with renal failure appear especially threatened by these far [9] .
complications. power settings of 5-7.5 W ) has been used successfully
